John CS, Vilner BJ, Gulden ME, et al. Synthesis and Pharmacological Characterization of 4-[125I]-N-( N-benzylpiperidin-4-yl )-4-iodobenzamide: a High Affinity Sigma Receptor Ligand for Potential Imaging of Breast Cancer[J]. Cancer Res, 1995 , 55(14): 3022 - 3027.
Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal Study of Iodine I-131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lym-phomas[J]. J Clin Oncol, 2001, 19: 3 908 -3 911.
[5]
Waterhouse RN, Collier TL. In Vivo Evaluation of [18F]l-(3-fluoropropyl)-4- (4-cyanophenoxy-methyl) piperidine: a Selective Sigma-1 Receptor Radioligand for PET[J]. Nucl Med Biol, 1997 , 24(2): 127 - 134.
[6]
Vose JM, Wahl RL, Saleh M, et al. Muticenter Phase Ⅱ Study of Iodine I-131 Tositumomab for Chemotherapy-relapsed/refractory Low-grade and Transformed Low-grade B-cell Non-Hodgkin's Lymphomas[J]. J Clin Oncol, 2000, 18:1316 -1323.
[7]
John CS, Gulden ME, Vilner BJ, et al. Synthesis, in Vitro Validation and in Vivo Pharma-cokinetics of [125I]N-[2-(4-iodophenyl)ethyl]-N-methyl-2-(1-piperidinyl) Ethylamine: a High-affinity Ligand for Imaging Sigma Receptor Positive Tumors [J]. Nucl Med Biol, 1996, 23(6): 761 - 766.
[8]
Seldin DW. Techniques for Using Bexxar for the Treatment of Non-Hodgkin's Lymphoma[J]. J Nucl Med Technol, 2002, 30:109-114.
Shiue C,Shiue GG,Benard F,et al. N-(n-Ben-zylpiperidm-4-yl)-2-[18F] fluorobenzamide: a Potential Ligand for PET Imaging of Breast Cancer[J]. Nucl Med Biol, 2000, 27(8): 763-767.
